Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder

Samankaltaisia teoksia

• Efficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy
  Tekijä: Nelson, J. Craig, et al.
  Julkaistu: (2014)
• Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin–norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study
  Tekijä: Clayton, Anita H, et al.
  Julkaistu: (2014)
• Aripiprazole Treatment of Irritability Associated with Autistic Disorder and the Relationship Between Prior Antipsychotic Exposure, Adverse Events, and Weight Change
  Tekijä: Mankoski, Raymond, et al.
  Julkaistu: (2013)
• Aripiprazole Once-Monthly 400 mg: Comparison of Pharmacokinetics, Tolerability, and Safety of Deltoid Versus Gluteal Administration
  Tekijä: Raoufinia, Arash, et al.
  Julkaistu: (2017)
• Safety and Tolerability of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Post Hoc Analysis (studies CN138-139 and CN138-163)
  Tekijä: Nelson, J. Craig, et al.
  Julkaistu: (2009)